{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:40:10Z","timestamp":1759452010549,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"34","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["D43 TW010540","HHSN26620040073C","1R15AI128714-01"],"award-info":[{"award-number":["D43 TW010540","HHSN26620040073C","1R15AI128714-01"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["D43 TW010540","HHSN26620040073C","1R15AI128714-01"],"award-info":[{"award-number":["D43 TW010540","HHSN26620040073C","1R15AI128714-01"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["D43 TW010540","HHSN26620040073C","1R15AI128714-01"],"award-info":[{"award-number":["D43 TW010540","HHSN26620040073C","1R15AI128714-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["D43 TW010540","HHSN26620040073C","1R15AI128714-01"],"award-info":[{"award-number":["D43 TW010540","HHSN26620040073C","1R15AI128714-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.vaccine.2021.07.026","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T02:16:23Z","timestamp":1626747383000},"page":"4810-4816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal assessment of nonavalent vaccine HPV types in a sample of sexually active African American women from ten U.S. Cities"],"prefix":"10.1016","volume":"39","author":[{"given":"P.","family":"Madhivanan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Krupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Coudray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Colbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Ruiz-Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Bokulich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Narasimhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Mathee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.L.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Schwebke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Roe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.07.026_b0005","unstructured":"Centers for Disease Control and Prevention. Cancers Associated with Human Papillomavirus, United States\u20142010\u20132014; 2018."},{"key":"10.1016\/j.vaccine.2021.07.026_b0010","doi-asserted-by":"crossref","unstructured":"de Sanjose S, Serrano B, Tous S, et al. Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6\/11\/16\/18\/31\/33\/45\/52 and 58. JNCI Cancer Spectr 2018; 2(4): pky045.","DOI":"10.1093\/jncics\/pky045"},{"key":"10.1016\/j.vaccine.2021.07.026_b0015","unstructured":"Centers for Disease Control and Prevention. Human Papillomavirus (HPV) ACIP Vaccine Recommendations. Found at: https:\/\/wwwcdcgov\/vaccines\/hcp\/acip-recs\/vacc-specific\/hpvhtml Accessed on November 25, 2019; 2018."},{"issue":"32","key":"10.1016\/j.vaccine.2021.07.026_b0020","doi-asserted-by":"crossref","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","article-title":"Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Meites","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"1","key":"10.1016\/j.vaccine.2021.07.026_b0025","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/21645515.2018.1512453","article-title":"Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature","volume":"15","author":"Hirth","year":"2019","journal-title":"Hum Vaccin Immunother."},{"issue":"3","key":"10.1016\/j.vaccine.2021.07.026_b0030","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.vaccine.2010.10.051","article-title":"Worsening disparities in HPV vaccine utilization among 19\u201326 year old women","volume":"29","author":"Dempsey","year":"2011","journal-title":"Vaccine."},{"issue":"6","key":"10.1016\/j.vaccine.2021.07.026_b0035","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jadohealth.2010.09.015","article-title":"Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid","volume":"47","author":"Cook","year":"2010","journal-title":"J Adolesc Health."},{"issue":"6","key":"10.1016\/j.vaccine.2021.07.026_b0040","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jadohealth.2013.07.002","article-title":"Racial disparities in human papillomavirus vaccination: does access matter?","volume":"53","author":"Gelman","year":"2013","journal-title":"J Adolesc Health."},{"key":"10.1016\/j.vaccine.2021.07.026_b0045","unstructured":"National Cancer Institute. Human Papillomavirus (HPV) Vaccines. Found at: https:\/\/wwwcancergov\/about-cancer\/causes-prevention\/risk\/infectious-agents\/hpv-vaccine-fact-sheet#should-hpv-vaccines-be-given-to-women-who-are-already-infected-with-hpv-or-have-cervical-cell-changes Accessed on November 25, 2019 2019."},{"key":"10.1016\/j.vaccine.2021.07.026_b0050","unstructured":"US Food and Drug Administrattion. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old. Found at: https:\/\/wwwfdagov\/news-events\/press-announcements\/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-old Accessed on October 4, 2020. 2018."},{"key":"10.1016\/j.vaccine.2021.07.026_b0055","doi-asserted-by":"crossref","unstructured":"Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. J Infect Dis 2011; 204(4): 566\u2013573.","DOI":"10.1093\/infdis\/jir341"},{"key":"10.1016\/j.vaccine.2021.07.026_b0060","doi-asserted-by":"crossref","unstructured":"Alizon S, Murall CL, Bravo IG. Why Human Papillomavirus Acute Infections Matter. Viruses 2017; 9(10).","DOI":"10.3390\/v9100293"},{"key":"10.1016\/j.vaccine.2021.07.026_b0065","doi-asserted-by":"crossref","unstructured":"Castle PE, Rodriguez AC, Burk RD, et al. Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer. J Infect Dis 2011; 203(6): 814\u2013822.","DOI":"10.1093\/infdis\/jiq116"},{"key":"10.1016\/j.vaccine.2021.07.026_b0070","doi-asserted-by":"crossref","unstructured":"Perkins RB, Clark JA, Apte G, et al. Missed opportunities for HPV vaccination in adolescent girls: a qualitative study. Pediatrics 2014; 134(3): e666-674.","DOI":"10.1542\/peds.2014-0442"},{"key":"10.1016\/j.vaccine.2021.07.026_b0075","doi-asserted-by":"crossref","DOI":"10.1177\/1178633718825077","article-title":"Knowledge and awareness of human papillomavirus among college students in South Carolina","volume":"12","author":"Kasymova","year":"2019","journal-title":"Infect Dis (Auckl)."},{"issue":"11","key":"10.1016\/j.vaccine.2021.07.026_b0080","doi-asserted-by":"crossref","first-page":"e0187193","DOI":"10.1371\/journal.pone.0187193","article-title":"Catch-up HPV vaccination status of adolescents in relation to socioeconomic factors, individual beliefs and sexual behaviour","volume":"12","author":"Grandahl","year":"2017","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.vaccine.2021.07.026_b0085","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/infdis\/jiu414","article-title":"The cost-effectiveness of human papillomavirus vaccine catch-up programs for women","volume":"211","author":"Chesson","year":"2015","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2021.07.026_b0090","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/cid\/civ975","article-title":"Home screening for bacterial Vaginosis to prevent sexually transmitted diseases","volume":"62","author":"Schwebke","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.07.026_b0095","doi-asserted-by":"crossref","unstructured":"Sena AC, Lee JY, Schwebke J, et al. A silent epidemic: the prevalence, incidence and persistence of mycoplasma genitalium among young, asymptomatic high-risk women in the United States. Clin Infect Dis 2018; 67(1): 73\u201379.","DOI":"10.1093\/cid\/ciy025"},{"key":"10.1016\/j.vaccine.2021.07.026_b0100","unstructured":"ThermoFisher Scientific. TaqMan\u2122 Control Genomic DNA (human). Found at: https:\/\/wwwthermofishercom\/order\/catalog\/product\/4312660#\/4312660 Accessed on October 4, 2020 20."},{"issue":"51","key":"10.1016\/j.vaccine.2021.07.026_b0105","doi-asserted-by":"crossref","first-page":"13573","DOI":"10.1073\/pnas.1714712114","article-title":"Recurring infection with ecologically distinct HPV types can explain high prevalence and diversity","volume":"114","author":"Ranjeva","year":"2017","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"21","key":"10.1016\/j.vaccine.2021.07.026_b0110","doi-asserted-by":"crossref","first-page":"8569","DOI":"10.1158\/0008-5472.CAN-10-0621","article-title":"Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity","volume":"70","author":"Trottier","year":"2010","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.vaccine.2021.07.026_b0115","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-14-395","article-title":"Persistence, clearance and reinfection regarding six high risk human papillomavirus types in Colombian women: a follow-up study","volume":"14","author":"Soto-De Le\u00f3n","year":"2014","journal-title":"BMC Infect Dis."},{"issue":"3","key":"10.1016\/j.vaccine.2021.07.026_b0120","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/infdis\/jiu104","article-title":"Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection","volume":"210","author":"Wilson","year":"2014","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2021.07.026_b0125","doi-asserted-by":"crossref","unstructured":"Kelly H, Faust H, Chikandiwa A, et al. Human papillomavirus serology among women living with HIV: Type-Specific Seroprevalence, Seroconversion, and Risk of Cervical Reinfection. J Infect Dis 2018; 218(6): 927\u2013936.","DOI":"10.1093\/infdis\/jiy252"},{"issue":"8","key":"10.1016\/j.vaccine.2021.07.026_b0130","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01993-17","article-title":"Superinfection exclusion between two high-risk human papillomavirus types during a Coinfection","volume":"92","author":"Biryukov","year":"2018","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2021.07.026_b0135","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/ijc.27828","article-title":"Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis","volume":"133","author":"Rositch","year":"2013","journal-title":"Int J Cancer."},{"key":"10.1016\/j.vaccine.2021.07.026_b0140","doi-asserted-by":"crossref","first-page":"100202","DOI":"10.1016\/j.pvr.2020.100202","article-title":"Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial","volume":"10","author":"Ferris","year":"2020","journal-title":"Papillomavirus Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21009038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21009038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:59:01Z","timestamp":1759402741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21009038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":28,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0264410X21009038"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.07.026","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal assessment of nonavalent vaccine HPV types in a sample of sexually active African American women from ten U.S. Cities","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}